Navigation Links
Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
Date:8/29/2012

INDIANAPOLIS, Aug. 29, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the decision to stop ongoing clinical studies investigating pomaglumetad methionil, also known as mGlu2/3, for the treatment of patients suffering from schizophrenia. The decision was made after a recently conducted independent futility analysis concluded HBBN, the second of Lilly's two pivotal studies, was unlikely to be positive in its primary efficacy endpoint if enrolled to completion. The decision was not based on any safety signals.

Additionally, the recently completed Phase II study, HBCO, which investigated pomaglumetad methionil as an adjunctive treatment with atypical antipsychotics, did not meet its primary endpoint. 

Lilly is contacting study investigators to outline specific actions related to the close-out of each ongoing study. Lilly will work with study investigators to ensure an appropriate transition of study participants to continuing clinical care outside of the trials.

"I'm disappointed in what these results mean for patients with schizophrenia who still are searching for options to treat this terrible illness," said Jan Lundberg, Ph.D., executive vice president, science and technology, and president, Lilly Research Laboratories.  "While there are many challenges in this complex field of research, neuroscience remains a core area of focus at Lilly. Our clinical development pipeline includes nearly a dozen neuroscience molecules being studied to treat illnesses such as depression, bipolar disorder and cognitive impairment associated with schizophrenia."

The decision to stop ongoing Phase III development of pomaglumetad methionil is expected to result in a third-quarter charge to R&D expense in the range of $25 million to $30 million (pre-tax), or approximately $0.02 per share (after-tax).  The company's previously-issued financial guidance for 2012 remains unchanged.

About Lilly's Pipeline
Lilly currently has a number of unique potential medicines in its Phase III clinical development pipeline, representing a variety of therapeutic areas including diabetes (4), cancer (3), neuroscience (2) and autoimmune diseases (2).  To learn more about the molecules in Lilly's clinical development pipeline, please visit Lilly's interactive pipeline website available at Lilly.com/pipeline.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

This press release contains forward-looking statements about the impact of ending studies of pomaglumetad methionil for the treatment of schizophrenia, and reflects Lilly's current beliefs. The financial information included in this release is an estimate only. For further discussion of risks and uncertainties affecting the company's business, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

P-LLY

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. U.S. Court of Appeals Upholds Validity of Lillys Alimta Compound Patent
2. Lilly Revises 2012 Reported Guidance to Reflect Income from Early Payment of Amylin Obligations
3. Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures
4. Lilly Supports Research to Determine What a Dogs Nose Knows About People with Diabetes and Severe Hypoglycemia
5. Lilly Reports Second-Quarter 2012 Results, Raises 2012 EPS Guidance
6. Lilly Confirms Date and Conference Call for Second-Quarter 2012 Financial Results Announcement
7. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
8. Lilly Diabetes Announces Once Upon A Time Contest Winner
9. Lilly Statement on Affordable Care Act Ruling by Supreme Court
10. Lilly Statement on PDUFA Vote by Senate
11. PrimeraDx Announces Commencement of Product Development Collaboration with Eli Lilly and Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 2, 2016  PipelineRx, a leading medication management ... offering demonstrations of its SaaS-based telepharmacy platform, ... Pharmacists 2016 Midyear Clinical Meeting and Exhibition, December ... With nearly 300 hospital clients nationally, the Company ... designed to dramatically improve pharmacy operations, enhance patient ...
(Date:12/2/2016)... -- On Thursday, December 1st 2016, the ... development and innovation in the biopharmaceutical industry at its ... the presence of Sergey Tsyb, Vice Minister of Industry ... , Natalia Sanina, First Vice Chairman of the State ... Roszdravnadzor, National Service of Control in Healthcare, Sergey Muravev, ...
(Date:12/2/2016)... Dec. 2, 2016  Eli Lilly and Company (NYSE: ... for 2017 and provide updated financial guidance for 2016 ... a conference call on that day with the investment ... guidance. The conference call will begin at ... can access a live webcast of the conference call ...
Breaking Medicine Technology:
(Date:12/2/2016)... Phoenix (PRWEB) , ... December 02, 2016 , ... ... statewide documentary on the perils of heroin that was watched live by 1 ... national Alfred I. duPont-Columbia University Award. , ASU students at the Walter Cronkite ...
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, a trusted name ... free trial program for all of the company’s desktop riser products. A simple ... free experience. , FlexiSpot’s unique desktop risers use an advanced dual gas spring ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s newest campaign, “Digestive Heath,” ... living proof that attitude and determination can combine into the most remarkable achievements. ... the holidays. This campaign will offer patients a new-found hope, by seizing the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... Regency Waikiki Beach Resort and Spa in Honolulu, offering local frontline clinicians the ... pain management. , The demand for supplemental training related to pain management ...
(Date:12/2/2016)... ... 2016 , ... "Pro3rd Accents Volume 2 is a set of 30 accented ... with just a few clicks of the mouse," said Christina Austin - CEO of ... Choose from various styles with accented animations, rigid boxes, simplistic lines, and more. In ...
Breaking Medicine News(10 mins):